Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
Oncology

Orthotopic CRC Modeling in NKG Mice Mirrors Human Disease

Cyagen Technical Content Team | July 08, 2025
Find Cyagen's Immunodeficient Mouse Models
Optimize your oncology studies with validated immunodeficient models and expert support.
Find Cyagen's Immunodeficient Mouse Models
Contents
01. Introduction to Colorectal Cancer Orthotopic Transplantation Model 02. Exploration of Colonic In-Situ Surgical Modeling Sites 03. Case Study of Colorectal Cancer Orthotopic Transplantation NKG Model 04. Transplantation Model Services: Orthotopic, NKG Immunodeficient Mice, and More

Colorectal cancer is a common malignant tumor that occurs in the colon, predominantly in the junction between the rectum and sigmoid colon. It ranks as the third most common gastrointestinal tumor with the highest incidence in the age group of 40 to 50 years, with a male-to-female ratio of 2-3:1. Colorectal cancer mainly comprises adenocarcinoma, mucinous adenocarcinoma, and undifferentiated carcinoma, with various morphologies including polypoid or ulcerative forms. Susceptible populations include individuals with chronic colitis, colon polyps, and obese males.

Orthotopic animal models of colorectal cancer, involving In-situ transplantation of colon cancer cells, can simulate the occurrence and development of human colon cancer to some extent, providing a valuable platform for researching the occurrence, development, biological characteristics, and treatment of human colon cancers.

Introduction to Colorectal Cancer Orthotopic Transplantation Model

Compared to heterotopic transplantation, orthotopic transplantation colorectal cancer models can better reflect the real conditions of the tumor and enhance the reliability of the tumor model. In the orthotopic or in-situ transplantation model, metastasis can be induced, indicating the interaction between tumor cells and organ-specific factors, which is associated with the development of colorectal cancer. In-situ transplantation can also simulate the tumor immune microenvironment. Therefore, most results based on heterotopic models need further validation through orthotopic transplantation models to assess results in a more clinically-relevant tumor microenvironment. Colorectal cancer's in-situ growth better replicates the tumor microenvironment for tumor cell growth in vivo and provides a more accurate prediction of drug efficacy for preclinical evaluations.

Exploration of Colonic In-Situ Surgical Modeling Sites

The thin and delicate colonic wall in mice makes in-situ injection surgery in the colon wall challenging. In human anatomy, the area where blood vessels, lymphatics, and nerves enter and exit the intestinal wall is referred to as the mesenteric border. Here, the intestinal wall is enclosed by two layers of peritoneum, forming the mesenteric triangle. In mouse anatomy, the equivalent of the "mesenteric border" in human anatomy is called the "intestinal mesenteric attachment site." However, in mouse anatomy, there is no concept of the "mesenteric triangle." The triangular area formed by the colonic wall and the two layers of peritoneum at the cecal mesenteric attachment site in mice is defined as the "cecal mesenteric triangle." In this region, the colonic wall lacks serosal covering, and blood vessels, lymphatics, and nerves enter and exit. An orthotopic implantation mouse model of colorectal cancer is established by surgically exposing the cecum of mice and in-situ implantation of fluorescently labeled colon cancer cells into the cecal mesenteric triangle.

The tissue within the cecal mesenteric triangle is loose, and the resulting blister formation following injection is distributed in a striated pattern along the cecal mesenteric attachment site. This formation has low tension, making it less prone to leakage. The tumor is located on one side of the cecal mesentery and is distributed along the axis of the cecum. Additionally, the cecal lumen is spacious, reducing the likelihood of intestinal obstruction in the short term.

Notably, the colonic wall at the cecal mesenteric triangle lacks serosal covering, which facilitates the growth of implanted colon cancer cells. Mesenteric arteries, veins, and lymphatic vessels in the cecal mesentery triangle enter and exit the intestinal wall, providing a rich blood supply that outflows into the portal venous system. Tumors in this area are more likely to invade mesenteric blood vessels and lymphatic vessels, leading to distant metastasis of colon cancer, with a particularly higher incidence of liver metastasis.

Tumor tissue in the colorectal cancer model can metastasize to multiple locations within the abdominal cavity, including the liver, spleen, diaphragm, and mesenteric lymph nodes. The metastatic pathways align with the characteristics of human colorectal cancer metastasis, enabling a complete simulation of the natural metastatic process of colorectal cancer.

Case Study of Colorectal Cancer Orthotopic Transplantation NKG Model

⮚ HCT116-luc cell line

In vivo Fluorescence Imaging, Fluorescence Intensity Changes, and Survival Curve of HCT116-luc Colorectal Cancer Cells Colon Orthotopic Transplantation Tumor NKG mouse model.

In vivo Fluorescence Imaging, Fluorescence Intensity Changes, and Survival Curve of HCT116-luc Colorectal Cancer Cells Colon Orthotopic Transplantation Tumor NKG mouse model.

Figure 1. In vivo Fluorescence Imaging, Fluorescence Intensity Changes, and Survival Curve of HCT116-luc Colorectal Cancer Cells Colon Orthotopic Transplantation Tumor NKG mouse model.

The results indicate that HCT116-luc readily forms tumors on Cyagen’s NKG mice, with the highest fluorescence signal reaching up to 1010. The maximum survival period for the mice is 27 days, with a median survival of 26 days, indicating a short survival duration. The tumor tissue metastasizes within the abdominal cavity, and after a certain period of proliferation (D25), internal calcifications occur in the tumor tissue, corresponding to a decrease in the fluorescence signal in the mice.

⮚ HCT15-luc cell line

In vivo fluorescent imaging of HCT15-luc colorectal cancer cells transplanted in the colon of NKG mice, fluorescence intensity change chart, and survival curve chart in mice.

In vivo fluorescent imaging of HCT15-luc colorectal cancer cells transplanted in the colon of NKG mice, fluorescence intensity change chart, and survival curve chart in mice.

Figure 2. In vivo fluorescent imaging of HCT15-luc colorectal cancer cells transplanted in the colon of NKG mice, fluorescence intensity change chart, and survival curve chart in mice.

The results indicate that HCT15-luc easily forms tumors on NKG, with a maximum fluorescence signal intensity reaching 108. The highest survival period for mice was 39 days, with a median survival of 35 days, indicating a relatively short survival duration, and tumor tissue metastasis occurred within the abdominal cavity.

⮚ DLD-1-luc cell line

In vivo fluorescent imaging of DLD-1-luc colorectal cancer cells transplanted in the colon of NKG mice, fluorescence intensity change chart, and survival curve chart.
In vivo fluorescent imaging of DLD-1-luc colorectal cancer cells transplanted in the colon of NKG mice, fluorescence intensity change chart, and survival curve chart.

Figure 3. In vivo fluorescent imaging of DLD-1-luc colorectal cancer cells transplanted in the colon of NKG mice, fluorescence intensity change chart, and survival curve chart.

The results indicate that DLD-1-luc easily forms tumors on NKG, with a maximum fluorescence signal intensity reaching 109. The highest survival period for mice was 63 days, with a median survival of 59 days, indicating a relatively longer survival duration, and tumor tissue metastasis occurred within the abdominal cavity.

Transplantation Model Services: Orthotopic, NKG Immunodeficient Mice, and More

Cyagen’s NKG mice are a type of severe immunodeficient mouse developed by Cyagen by deleting the Il2rg gene from the NOD-Scid strain. This strain lacks mature T, B, and NK cells, has reduced complement activity, and weak macrophage phagocytosis of human cells. As a result, NKG mice can efficiently engraft human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), patient-derived xenografts (PDX), or adult stem cells and tissues.

Cyagen has successfully transplanted over 200 human cell lines into immunodeficient mice, including subcutaneous, intravenous, heterotopic, and orthotopic/in-situ implantation sites. This has resulted in the development of numerous orthotopic transplantation models involving various cancers such as colorectal cancer, lung cancer, and liver cancer. If you have any orthotopic or other transplant modeling needs, please feel free to contact us for a free consultation!

Subscribe to Receive Updates & Promotions From Cyagen
Subscribe
* Your privacy matters to us. We never share it with third parties.
Explore More
Accelerating Alzheimer's Research Using Advanced iPSC Platforms
MND Awareness Day 2026: Overcoming ALS Drug Development Bottlenecks with Predictive In Vivo Tools
The PROTAC Era: From VEPPANU’s Landmark Approval to the Next Generation of CRBN-Targeted Therapies
Beyond TfR1? IGF1R Unlocks Ultra-Rapid BBB Crossing and Superior Muscle siRNA Delivery
Share
Top
Ready to Elevate Your Research?
Discover how Cyagen can support your research. Let’s start a conversation.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research